Αποτελέσματα Αναζήτησης
This is a summary of the European public assessment report (EPAR) for Vaniqa. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vaniqa. Expand all.
15 Ιουλ 2024 · Vaniqa cream is used to reduce unwanted facial hair in women. Vaniqa cream does not permanently remove facial hair or prevent hair growth. Warnings. Vaniqa cream is for external use only. Continue to use Vaniqa even if you do not see immediate results. Reduction in facial hair occurs gradually.
Αναλυτικές πληροφορίες συστατικών, κυκλοφορίας και τρόπου χρήσης του φαρμάκου vaniqa
ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ. 1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ. Vaniqa 11,5% κρέμα. 2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ. Κάθε γραμμάριο κρέμας περιέχει 115 mg εφλορνιθίνης (ως υδροχλωριούχο μονοϋδρική). Έκδοχα με γνωστή δράση: .
30 Οκτ 2022 · VANIQA® (eflornithine hydrochloride) cream, 13.9% is indicated for the reduction of unwanted facial hair in women. VANIQA® has only been studied on the face and adjacent involved areas under the chin of affected individuals. Usage should be limited to these areas of involvement.
Vaniqa, INN-eflornithine. ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. Vaniqa 11.5% cream. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each gram of cream contains 115 mg of eflornithine (as hydrochloride monohydrate). Excipients with known effect:
Vaniqa significantly reduced how bothered patients felt by their facial hair and by the time spent removing, treating, or concealing facial hair. Patient comfort in various social and work settings was also improved.
